Submission Status Graadian Agency for Drugs and Technologies Product: Rapaflo Generic Name: silodosin Manufacturer: Watson Pharma Company Indication: Treatment of benign prostatic hyperplasia (BPH) Submission Type: Initial Date Submission Received: 2011-Oct-25 Date NOC Issued: 2011-Jan-11 Targeted CDEC Meeting: 2012-Mar-21 Priority Review Granted: Not Requested Target Target Time Date Submisso Days)	ents
Drugs and Technologies in Health Generic Name: silodosin Manufacturer: Watson Pharma Company Indication: Treatment of benign prostatic hyperplasia (BPH) Submission Type: Initial Date Submission Received: 2011-Oct-25 Date Submission Received: 2011-Oct-25 Date ODEC Meeting: 2012-Mar-21 Priority Review Granted: Not Requested Phase Target Time Target Date 2 CDR Date	ents
in Health Generic Name: silodosin Manufacturer: Watson Pharma Company Indication: Treatment of benign prostatic hyperplasia (BPH) Submission Type: Initial Date Submission Received: 2011-Oct-25 Date Submission Received: 2012-Mar-21 Priority Review Granted: Not Requested Phase Target Time Target Date 2 CDR Date	ents
Indication: Treatment of benign prostatic hyperplasia (BPH) Submission Type: Initial Date Submission Received: 2011-Oct-25 Date NOC Issued: 2011-Jan-11 Target ODEC Meeting: 2012-Mar-21 Priority Review Granted: Not Requested Target Target Target Actual Comm Phase Target Target CDR Date Comm	lents
Submission Type: Initial Date Submission Received: 2011-Oct-25 Date Submission Received: 2011-Oct-25 Targeted CDEC Meeting: 2012-Mar-21 Priority Review Granted: Not Requested Phase Target Time Target Date 2 Actual CDR Date Comm	uents
Date Submission Received: 2011-Oct-25 Date NOC Issued: 2011-Jan-11 Targeted CDEC Meeting: 2012-Mar-21 Priority Review Granted: Not Requested Phase Target Time Target Date 2 Actual CDR Date Comm	ents
Targeted CDEC Meeting: 2012-Mar-21 Priority Review Granted: Not Requested Phase Target Time Target Date 2 Actual CDR Date Comm	ents
Target Target Actual Comm	ents
Phase Time Date ² CDR Date Comm	ents
1 Submission deemed complete 5 2011-Nov-01 2011-Nov-01	
2 Patient group input submission received ³ 2011-Nov-17 - Call for patient input posted on - Patient group input deadline: 2 - No patient group input submission	011-Nov-17
3 CADTH Reviewers' Reports sent to Manufacturer ⁴ 45 2012-Jan-23 2012-Jan-23	
4 Comments from Manufacturer on Reviewers' Reports Received by CADTH 7 2012-Feb-01 2012-Feb-01	
5 CDEC Meeting 2012-Mar-21 2012-Mar-21	
6 CDEC Recommendation Sent to Drug Plans and Manufacturer 5 to 7 2012-Mar-28 2012-Mar-28	
7Embargo Period 5 Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation102012-Apr-122012-Apr-10	
Final Recommendation sent to Drug Plans and Manufacturer Final Recommendation sent to Drug Plans and Manufacturer 5 2012-Apr-19 2012-Apr-19 - Notice of Final Recommendation 8 (a) (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved) 5 2012-Apr-19 2012-Apr-19 - Notice of Final Recommendation	on Issued
OR	
8 (b) Clarification and Final Recommendation sent to Drug Plans and Manufacturer Plans and Manufacturer (Clarification Requested, no Request for Reconsideration made) 5	
OR CR	
8 (c) Placed on CDEC Agenda For Reconsideration (At Manufacturer's request) 25 Depends on Meeting Dates	
9 Final Recommendation sent to Drug Plans and Manufacturer 5	

¹ Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.

² The target dates for this report are based on the CDEC meeting schedule, which is posted on www.cadth.ca.

³ The deadline for Patient Group Input is 15 business days after CADTH receives the Submission or up to 25 business days if advance notice of a Submission is received from the Manufacturer.

⁴ Target time is calculated, based on the date the Reviewers receive copies of the Manufacturer's Submission. Target time does not include the time allocated for receipt of Manufacturer's binders (5 business days) and time allocated for distribution of binders to reviewers (3 business days).

⁵The Recommendation is held in confidence by all stakeholders and not acted upon until after CADTH has issued the notice of Final Recommendation.

This Submission Status Report reflects status as of Thursday noon.